Medicines Distribution Consent




1546 NEW ZEALAND GAZETTE No. 67

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any)

--- | --- | --- | ---
Bovine serum 0.6 µg, goat anti-mouse polyclonal antibody 4.9 µg, murine monoclonal antibody to alpha HCG 0.9 µg, murine monoclonal antibody to beta HCG 1.8 µg | Test kit, pregnancy | Syntron Bioresearch Inc., Vista, California, United States of America | Perfectly Clear Midstream Pregnancy Test

Bovine serum 1 µg, goat anti-mouse polyclonal antibody 8 µg, murine monoclonal antibody to alpha HCG 1.5 µg, murine monoclonal antibody to beta HCG 3 µg | Test kit, pregnancy | Syntron Bioresearch Inc., Vista, California, United States of America | Perfectly Clear Pregnancy Test Strip

Chromium trichloride (anhydrous) 20.4 µg/mL, copper chloride (dihydrate) 536 µg/mL, manganese chloride 288 µg/mL, zinc chloride 2,084 µg/mL | Injection, concentrate | David Bull Laboratories Limited, Mulgrave North Victoria, Australia | Trace Elements

Iopamidol 498.72 mg/mL equivalent to 240 mg/mL iodine | Injection, solution | Schering AG., Berlin, Germany | Ultravist 240

Dated this 3rd day of June 1999.

G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

GO4117

Consent to the Distribution of Changed Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act, and are set out in the Schedule hereto:

Schedule

Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any)

--- | --- | --- | ---
Fluconazole 50 mg, 100 mg, 150 mg, 200 mg | Capsules | Pfizer Laboratories SA., Amboise Cedex, France; and Pfizer Pty Limited, West Ryde, New South Wales, Australia | Diflucan

Fluconazole 2 mg/mL | Infusion, solution | Pfizer Laboratoires SA., Amboise Cedex, France | Diflucan

Flixotide 50 µg/dose | Inhaler, aerosol, metered | Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom; and Glaxo Wellcome Production, Evreux, France | Flixotide

Adsorbed tetanus vaccine 10 LfU/mL, diphtheria CRM197 protein conjugate 50 µg/mL, diphtheria toxoid (adsorbed) 25 LfU/mL, haemophilus influenzae type b vaccine 20 µg/mL, pertussis vaccine (adsorbed) 32 IOU | Injection, suspension | Lederle Laboratories, division of American Cyanamid Co., Pearl River, New York, United States of America | Tetramune

Dated this 3rd day of June 1999.

G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

GO4118



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1999, No 67


NZLII PDF NZ Gazette 1999, No 67





✨ LLM interpretation of page content

🏥 Consent to the Distribution of New Medicines (continued from previous page)

🏥 Health & Social Welfare
3 June 1999
Medicines, Distribution, Pregnancy Test, Trace Elements, Iopamidol
  • G. R. Boyd, Chief Advisor, Regulation and Safety

🏥 Consent to the Distribution of Changed Medicines

🏥 Health & Social Welfare
3 June 1999
Medicines, Distribution, Fluconazole, Flixotide, Tetramune
  • G. R. Boyd, Chief Advisor, Regulation and Safety